D
ampening cellular electrical activity by pharmacological activation of specific types of K + channels has therapeutic potential for the treatment of a variety of disease states, including epilepsy, arrhythmias, vascular constriction, and various pain conditions (1, 2). Consequently, screening efforts have identified a number of agents that open different types of K + channels (2) , presumably by targeting their respective channel-specific activation mechanisms.
Distinct structural mechanisms enable K + channels to respond to a plethora of physiological stimuli, including voltage, temperature, mechanical force, and various second messengers, such as adenosine triphosphate (ATP), Ca 2+ , and H + , as well as bioactive lipids such as phosphatidylinositol 4,5-bisphosphate (PIP 2 ) and arachidonic acid (3, 4) . However, despite this complexity, these activation pathways seem to converge on the two principal mechanisms known to gate K + channels open: dilation of the "lower" gate at the intracellular pore entrance used by inwardly rectifying (K ir ) (5) and voltage-gated (K v ) K + channels (6) , and activation of the selectivity filter (SF) gate used by most two-pore domain K + (K 2P ) channels (4, 7, 8) and Ca 2+ -activated big-conductance K + (BK Ca ) channels (9, 10) . In voltage-gated hERG (human ether-à-go-go-related gene) channels, both mechanisms coexist, with voltage opening the lower gate but rapid inactivation occurring through closure of the SF gate (11, 12) . Here we identify a common mechanism for drug-induced channel opening that bypasses these physiological activation mechanisms in SF-gated K + channels. For the mechanosensitive K 2P channels TREK-1 and TREK-2, the voltage-gated hERG channel, and the Ca 2+ -activated BK Ca channel, a series of small-molecule activators all harboring a negatively charged group (tetrazole or carboxylate) have been proposed to act as selective channel openers [i.e., BL-1249 for TREK-1/-2 (13); PD-118057 for hERG (14) ; and NS11021 for BK Ca (15) ]. However, application of these compounds to their respective "nontarget" channels revealed an unexpected polypharmacology: All three openers displayed equal efficiency in opening TREK-1 channels (Fig. 1A ) and hERG channels (Fig. 1B) , as well as BK Ca channels (Fig. 1C) , whose activation curve is strongly shifted to more negative voltages ( fig. S1C ). This suggests that these activators may not target channel-specific activation mechanisms and may instead share a common mechanism. In all cases, the compound-mediated effect was effectively antagonized by large quaternary ammonium ions (QA L + ) such as tetra-pentylammonium (TPenA) or tetra-hexyl-ammonium (THexA) that are known to block K + channels at a site immediately below the inner entrance to the SF (16) (Fig. 1, A and B, and fig. S1C ). Likewise, all these activators reduced the QA L + -mediated inhibition in these different K + channels (Fig. 1C and figs . S1, A and B, and S7, A and B). Furthermore, extended screening with BL-1249 also revealed potent activation of several other K 2P channels (TREK-2, TRAAK, TALK-1, TALK-2, THIK-1, and THIK-2; fig. S1D ). Together, these data suggest that these negatively charged activators (NCAs) (BL-1249, PD-118057, and NS11021) act on a gating mechanism that is shared among these different classes of K + channels and that their action involves a site that overlaps with the conserved QA L + -binding site located below the SF.
A distinctive feature of all NCA-responsive K + channels is their gating by the SF, a mechanism that is intimately coupled to ion permeation (17, 18) . In K 2P channels, this coupling leads to pronounced activation by Rb + , which displays an ion occupancy distinct to K + at the four SF K + binding sites (S1 to S4) that stabilizes the activated state of the SF gate (17) . Interestingly, Rb + not only activated all NCAresponsive K 2P channels but also led to robust activation of BK Ca and hERG channels (Fig. 1D) . By contrast, Rb + failed to exert any activatory effect on K + channels gated at the helix-bundle crossing (i.e., K ir and most K v channels), as was observed for K v 1.1, K v 1.5, K v 3.1, and K ir 1.1 (Fig.  1D) ; consistent with this, these channels were also not activated by BL-1249 (fig. S2, A to E). Furthermore, cyclic nucleotide-gated channels that are also gated at the SF were not activated by BL-1249, indicating that the NCA mechanism may be specific to SF-gated K + channels ( fig. S2F ).
To gain further mechanistic insight into channel opening by the NCAs, we next investigated their binding by x-ray crystallography, cysteinescanning mutagenesis, and atomistic molecular dynamics (MD) simulations. First, anomalous diffraction data were collected from TREK-2 channels cocrystallized with a brominated derivative of BL-1249 (BL-1249 Br ) ( Fig. 2A; fig. S3 , A to C; and supplementary materials and methods). Although no discrete electron density was visible for BL-1249 itself, in anomalous difference maps, two bromine peaks were clearly visible per TREK-2 dimer ( fig. S3, A and B) and the main-chain protein backbone showed excellent agreement with a previously crystallized high-resolution structure of TREK-2 [Protein Data Bank (PDB) 4XDJ] (19) . Both bromine anomalous difference peaks were located at the entrance of the side fenestrations branching off the central pore cavity below the SF. Comparison with a structure that included QA L + (16) showed that these bromine positions reside within the spherical volume of THexA but outside that of the smaller tetra-ethyl-ammonium (TEA) ion. Consistent with this, BL-1249 activation of TREK-2 channels was antagonized by THexA but not by TEA (Fig.  2, B and C) .
These structural data were complemented by cysteine-scanning mutagenesis of the pore-lining M2 and M4 helices of TREK-1. Six residues, including the highly conserved Pro 183 (P183) and Leu 304 (L304) (also investigated in TREK-2, fig.  S3D ), were identified where mutations markedly reduced the apparent affinity of BL-1249. These residues cluster around the bromine densities detected in the TREK-2 cocrystal with BL-1249 Br ( Fig. 2D and fig. S3, C and D →Cys) channels was markedly slowed by the presence of BL-1249 (Fig. 2, E  and F ). This effect was specific for BL-1249, as two further channel activators with distinct binding sites [2-APB at the C terminus (21) and ML335 behind the SF (22) ] both failed to slow this rate (Fig. 2, E and F) . Furthermore, TREK-1 activation with 2-APB or ML335 was not antagonized by QA L + inhibition, and mutations at the BL-1249 site did not affect 2-APB activation ( fig. S4, A, B , and E).
In addition, we performed MD simulations to examine the orientation of BL-1249
Br within its proposed binding site (Fig. 2G) . The favored binding pose oriented the negatively charged tetrazole group of BL-1249 toward the S6 "cavity binding site" for K + just below the SF. The remainder of the BL-1249 molecule engaged with residues in M2 and M4 consistent with our scanning mutagenesis data (Fig. 2D and fig. S3D ). Moreover, the bromine atom in these simulations was found to be within 3 to 4 Å of the bromine densities determined by crystallography ( fig. S3E ). Together, these data indicate that BL-1249 binds to a site below the SF and reveal a critical role of the negative charge of the acidic tetrazole ring (pK a around 5, where K a is the dissociation constant), implying a pH-dependent compound efficacy. Indeed, when tested with the K 2P channel TALK-2 [exhibiting little intrinsic intracellular pH (pH i ) sensitivity], BL-1249 potency dropped strongly with a lowering of the solution pH i to 5, whereas control experiments with 2-APB lacked this pH dependence (Fig. 3F) .
We have recently used atomistic MD simulations and a double-bilayer setup to study ion permeation in the TRAAK K 2P channel (17) . Therefore, we carried out simulations of ion permeation in Schewe TRAAK with BL-1249 modeled into the equivalent site in the TRAAK channel structure (PDB 4I9W) (Fig. 3A) . This indicated several changes induced by BL-1249: (i) K + occupancy at the S6 site located adjacent to the negatively charged tetrazole group of BL-1249 increased~16-fold (Fig. 3, A and B) , (ii) K + occupancy of the S1 and S4 sites increased (Fig. 3B) , and (iii) the rate of K + permeation increased by 1.6-fold (24 ± 2 ions/ ms compared to 15 ± 2 ions/ms without BL-1249; Fig. 3C ).
The effect of BL-1249 on ion permeation was further investigated with single-channel recordings of TREK-2 expressed in human embryonic kidney (HEK) 293 cells. Besides an increase in open probability, an increase in the measured single-channel amplitude was also observed in both the inward (from −29.3 ± 1.5 to −34.1 ± 1.9 pA at −100 mV; n = 7) and outward (from 17.7 ± 1.3 to 21.7 ± 1.4 pA at +100 mV; n = 7) directions in response to BL-1249 (Fig. 3, D and E). This result is consistent with the observed increase in SF ion occupancy at S1 and S4 that is expected to enhance ion permeation via a direct knock-on effect for ions entering the SF from either side (23) . A similar increase in unitary conductance was also observed for TREK-1 channels recorded in patches from Xenopus oocytes ( fig. S4, A to C) . Notably, increases in single-channel conductance have not been observed upon activation of TREK-1, TREK-2, or TRAAK K 2P channels by other physiological stimuli (24, 25) .
Collectively, these results indicate that BL-1249 increases ion permeation and channel-open probability by influencing K + occupancy at sites below and within the SF. In line with this notion, mutations in the SF that change filter ion occupancy at the S1 and S4 sites (17, 26) and induce the activated "leak mode" in K 2P channels (17) also render them insensitive to BL-1249 (and various other activators discussed below; fig. S6 , A to D).
The negatively charged moiety identified within BL-1249, PD-118057, and NS11021 is also found in a series of known activators of TREK-1 and TREK-2 K 2P channels [ML67-33 (27) (27, 31) . Indeed, these compounds also share all the hallmark features of BL-1249 action, including polypharmacology [i.e., mutual activation of K 2P , BK Ca , and hERG channels (Fig. 4, C  and D) , sensitivity to QA L + ( Fig. 4A; fig. S7 , A to C; and tables S2 and S3] and mutations that reduce BL-1249 activation in TREK-1 (fig. S4, C  and D) . In addition, MD simulations of their interaction with structures of the TREK-2, BK Ca , and hERG channel pores identified similar stable binding poses below the SF with orientation of the negative moiety toward the cavity and a concomitant increase in K + occupancy at cavity and SF ion binding sites (Fig. 4, C and D, and figs.  S7D and S8, A to C) . Notably, this assumed NCA binding site overlaps with the "promiscuous inhibitor binding site" in the hERG channel, which underlies drug-induced long QT syndrome (12, 32) . This site is thought to accommodate many hydrophobic molecules (e.g., terfenadine), and consistent with this, we found that activation by PD-118057 strongly reduced inhibition by terfenadine (Fig. 4B) .
The molecular features of the NCA compounds define a common pharmacophore that, besides the negatively charged group, comprises both aromatic and hydrophobic moieties (Fig. 4E) . As a control, we tested tetrazole-containing compounds that do not fit this common pharmacophore on TREK-1, BK Ca , and hERG channels and found that they were unable to promote channel activation ( fig. S9, A to C) .
Our results uncover a class of K + channel openers, the NCAs, that act as a universal master key to unlock the SF gate. Mechanistically, these NCAs bind below the SF, where their negative charge promotes K + binding to the pore cavity, and thereby also alter the ion occupancy in the SF in a way that is known to promote activation of the filter gate (17) . We hypothesize that, in particular, the increase at the S1 and S4 sites is responsible for activating the SF gate because all NCA-responsive channels are also activated by Rb + permeation, which is thought to increase ion occupancy at these sites, whereas mutations known to reduce S1 and S4 ion occupancy in K 2P channels abolish NCA activation. Furthermore, a loss of K + binding to the S1 site has been implicated in SF inactivation in K v channels (33), hERG channels (32), and TREK-2 K 2P channels (19) . However, at this time, we cannot exclude the possibility that nonelectrostatic interactions of the NCAs with their respective binding sites also contribute to the stabilization of the active SF state because these sites involve gating-sensitive regions [i.e., the TM4 (8, 19) and S6 segments (6, 34) ]. In any case, our results support the view that many K 2P channels, as well as BK Ca channels, adopt a low-activity (i.e., inactivated) state of their SF at rest and that the various physiological stimuli induce structural changes that drive the SF into an active (open) state. The NCAs appear to operate by means of bypassing these activation mechanisms to directly stabilize the SF in its active state. In addition, our findings have important implications for the development of drugs that target K + channels, because they reveal the binding sites and the mechanism of action for many established activators in various K + channels. Our findings have also identified the first activators for several K 2P channels (e.g., TALK-1/-2 and THIK-1/-2). Notably, the NCA binding site overlaps with the promiscuous inhibitor site in hERG, and thus, targeting this NCA site might represent a promising approach to circumvent the druginduced long QT syndrome, which is, as of now, a serious burden in drug development (12) . However, the identified polypharmacology also represents a challenge for the development of any NCA-based compound into a highly subtypespecific K + channel agonist. Nevertheless, structural differences between K 2P , hERG, and BK Ca channels may still permit a rational drug design that reduces this promiscuity. However, in some acute situations such as ischemic stroke or status epilepticus, exploiting the polypharmacology of NCAs to promote simultaneous opening of multiple neuroprotective K + channels (e.g., BK Ca , TREK-1, TREK-2, TRAAK, THIK-1, and THIK-2) may even be beneficial. ). Error bars indicate SEM; the B and C superscripts indicate the subunit of the tetramer. (E) Representation of the K 2P , hERG, and BK Ca activators used to generate a common NCA pharmacophore consisting of aromatic (blue), hydrophobic (gray), and acidic (red) moieties, with distances and angles as shown.
